Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial.
Progress in biochemical pharmacology.
Times cited: 688
9-cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein.
Times cited: 99